NI201400003A - Una nueva composición terapéutica que contiene apomorfina como ingrediente activo - Google Patents
Una nueva composición terapéutica que contiene apomorfina como ingrediente activoInfo
- Publication number
- NI201400003A NI201400003A NI201400003A NI201400003A NI201400003A NI 201400003 A NI201400003 A NI 201400003A NI 201400003 A NI201400003 A NI 201400003A NI 201400003 A NI201400003 A NI 201400003A NI 201400003 A NI201400003 A NI 201400003A
- Authority
- NI
- Nicaragua
- Prior art keywords
- composition containing
- active ingredient
- therapeutic composition
- new therapeutic
- containing apomorphine
- Prior art date
Links
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 title abstract 2
- 229960004046 apomorphine Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que contiene apomorfina como principio farmacéutico activo, codisolvente, antioxidante, agua con un PH mayor que 4. La fórmulación farmacéutica es adecuada para la administración parenteral para el tratamiento de la enfermedad de Parkinson.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11290320A EP2545905A1 (en) | 2011-07-11 | 2011-07-11 | A new therapeutical composition containing apomorphine as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201400003A true NI201400003A (es) | 2015-10-12 |
Family
ID=46514305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201400003A NI201400003A (es) | 2011-07-11 | 2014-01-09 | Una nueva composición terapéutica que contiene apomorfina como ingrediente activo |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US11026938B2 (es) |
| EP (2) | EP2545905A1 (es) |
| JP (2) | JP6356064B2 (es) |
| KR (1) | KR101990897B1 (es) |
| CN (2) | CN103826612B (es) |
| AU (1) | AU2012283381B2 (es) |
| BR (1) | BR112014000306B1 (es) |
| CA (1) | CA2841807C (es) |
| CL (1) | CL2014000050A1 (es) |
| CO (1) | CO6870038A2 (es) |
| CR (1) | CR20140005A (es) |
| CU (1) | CU24159B1 (es) |
| DO (1) | DOP2014000003A (es) |
| EA (1) | EA025870B1 (es) |
| EC (1) | ECSP14013200A (es) |
| GE (2) | GEAP201813377A (es) |
| GT (1) | GT201400003A (es) |
| IL (1) | IL230308A (es) |
| IN (1) | IN2014DN00090A (es) |
| MA (1) | MA35411B1 (es) |
| MX (2) | MX389600B (es) |
| MY (1) | MY168212A (es) |
| NI (1) | NI201400003A (es) |
| PE (1) | PE20141539A1 (es) |
| PH (1) | PH12014500065A1 (es) |
| SG (1) | SG10201605491PA (es) |
| TN (1) | TN2014000001A1 (es) |
| UA (1) | UA113962C2 (es) |
| WO (1) | WO2013007381A1 (es) |
| ZA (1) | ZA201309711B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545905A1 (en) * | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
| PL2854764T3 (pl) | 2012-06-05 | 2019-07-31 | Neuroderm Ltd | Kompozycje zawierające apomorfinę i kwasy organiczne oraz ich zastosowania |
| EP2918266A1 (en) | 2014-03-11 | 2015-09-16 | CDRD Berolina AB | Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease |
| EP2979688A1 (en) * | 2014-08-01 | 2016-02-03 | Britannia Pharmaceuticals Limited | Composition containing Apomorphine and a Divalent Metal Cation |
| BR112017013749A2 (en) * | 2014-12-23 | 2018-03-27 | Neuroderm Ltd | apomorphine crystal forms and their uses |
| US20180280465A1 (en) | 2015-09-28 | 2018-10-04 | Ever Neuro Pharma Gmbh | Aqueous composition of apomorphine for subcutaneous administration |
| US12589095B2 (en) | 2019-05-31 | 2026-03-31 | Primo Pharmatech Llc | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient |
| WO2021026421A1 (en) * | 2019-08-07 | 2021-02-11 | Aclipse One Inc. | Pharmaceutical compositions of (6as)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol |
| GB201912686D0 (en) * | 2019-09-04 | 2019-10-16 | Reown Pharma Inc | Pharmaceutical composition |
| WO2021235436A1 (ja) | 2020-05-20 | 2021-11-25 | 株式会社メドレックス | アポモルヒネ含有経皮吸収型製剤 |
| WO2022271537A1 (en) * | 2021-06-25 | 2022-12-29 | President And Fellows Of Harvard College | Compositions and methods relating to injectable microemulsions |
| WO2023012736A1 (en) * | 2021-08-05 | 2023-02-09 | Zydus Lifesciences Limited | Stable pharmaceutical compositions of apomorphine |
| US20250361252A1 (en) | 2022-06-15 | 2025-11-27 | Ever Neuro Pharma Gmbh | Apomorphine prodrugs and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1662566A1 (ru) * | 1988-03-05 | 1991-07-15 | Всесоюзный Научно-Исследовательский Институт Биотехнологии | Способ стабилизации инъекционного раствора апоморфина |
| JP2822049B2 (ja) * | 1989-02-02 | 1998-11-05 | ゼリア新薬工業株式会社 | 水性製剤組成物 |
| DE69434304T2 (de) * | 1993-03-26 | 2005-12-29 | Merkus, Franciscus Wilhelmus H.M. | Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin |
| US6121276A (en) * | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
| US5945117A (en) | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| JP3723857B2 (ja) * | 1998-02-04 | 2005-12-07 | 日本ケミカルリサーチ株式会社 | ヒト成長ホルモン含有水性医薬組成物 |
| US6011043A (en) | 1998-06-19 | 2000-01-04 | Schering Corporation | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
| US6436950B1 (en) * | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
| US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
| BR0005797A (pt) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados |
| US20020169166A1 (en) | 2001-03-09 | 2002-11-14 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| US20030008878A1 (en) | 2001-03-09 | 2003-01-09 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| ITMI20011321A1 (it) * | 2001-06-22 | 2002-12-22 | Chiesi Farma Spa | Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del |
| US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
| PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| US6939094B2 (en) | 2003-01-28 | 2005-09-06 | Macro Technologies Inc. | Autonomous power interface for modifying limited rotation speed of a machine |
| EP1625165A2 (en) | 2003-04-03 | 2006-02-15 | Protein Design Labs, Inc. | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
| US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
| JP4901218B2 (ja) * | 2004-02-09 | 2012-03-21 | あすか製薬株式会社 | 併用医薬 |
| CA2652886A1 (en) | 2006-05-24 | 2007-11-29 | Bayer Schering Pharma Aktiengesellschaft | High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity |
| US20080171072A1 (en) * | 2006-08-11 | 2008-07-17 | Frank Burczynski | Ocular inserts containing apomorphine |
| US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| EP2057982A1 (en) * | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
| CN101712675B (zh) * | 2008-10-07 | 2013-07-03 | 江苏恒谊药业有限公司 | 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用 |
| EP2545905A1 (en) * | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
-
2011
- 2011-07-11 EP EP11290320A patent/EP2545905A1/en not_active Withdrawn
-
2012
- 2012-07-11 PH PH1/2014/500065A patent/PH12014500065A1/en unknown
- 2012-07-11 CU CU20140005A patent/CU24159B1/es active IP Right Grant
- 2012-07-11 JP JP2014519451A patent/JP6356064B2/ja active Active
- 2012-07-11 CN CN201280034745.9A patent/CN103826612B/zh active Active
- 2012-07-11 GE GEAP201813377A patent/GEAP201813377A/en unknown
- 2012-07-11 EP EP12735463.7A patent/EP2731589A1/en not_active Withdrawn
- 2012-07-11 WO PCT/EP2012/002916 patent/WO2013007381A1/en not_active Ceased
- 2012-07-11 IN IN90DEN2014 patent/IN2014DN00090A/en unknown
- 2012-07-11 CA CA2841807A patent/CA2841807C/en active Active
- 2012-07-11 CN CN201810378574.0A patent/CN108434094A/zh active Pending
- 2012-07-11 BR BR112014000306-8A patent/BR112014000306B1/pt active IP Right Grant
- 2012-07-11 MY MYPI2014000016A patent/MY168212A/en unknown
- 2012-07-11 PE PE2014000051A patent/PE20141539A1/es active IP Right Grant
- 2012-07-11 GE GEAP201213377A patent/GEP20196969B/en unknown
- 2012-07-11 KR KR1020147001302A patent/KR101990897B1/ko active Active
- 2012-07-11 SG SG10201605491PA patent/SG10201605491PA/en unknown
- 2012-07-11 AU AU2012283381A patent/AU2012283381B2/en active Active
- 2012-07-11 EA EA201400067A patent/EA025870B1/ru not_active IP Right Cessation
- 2012-07-11 UA UAA201400117A patent/UA113962C2/uk unknown
- 2012-07-11 MX MX2014000454A patent/MX389600B/es unknown
-
2013
- 2013-12-20 ZA ZA2013/09711A patent/ZA201309711B/en unknown
-
2014
- 2014-01-02 TN TNP2014000001A patent/TN2014000001A1/en unknown
- 2014-01-02 IL IL230308A patent/IL230308A/en active IP Right Grant
- 2014-01-07 CR CR20140005A patent/CR20140005A/es unknown
- 2014-01-09 GT GT201400003A patent/GT201400003A/es unknown
- 2014-01-09 NI NI201400003A patent/NI201400003A/es unknown
- 2014-01-09 DO DO2014000003A patent/DOP2014000003A/es unknown
- 2014-01-09 CL CL2014000050A patent/CL2014000050A1/es unknown
- 2014-01-10 US US14/152,000 patent/US11026938B2/en active Active
- 2014-01-10 MX MX2021010046A patent/MX2021010046A/es unknown
- 2014-02-03 MA MA36727A patent/MA35411B1/fr unknown
- 2014-02-04 CO CO14022989A patent/CO6870038A2/es unknown
- 2014-02-11 EC EC2014013200A patent/ECSP14013200A/es unknown
-
2016
- 2016-06-30 US US15/199,070 patent/US20160310480A1/en not_active Abandoned
- 2016-12-08 JP JP2016238705A patent/JP2017081947A/ja active Pending
-
2017
- 2017-12-13 US US15/840,585 patent/US20180098981A1/en not_active Abandoned
-
2021
- 2021-04-30 US US17/245,209 patent/US11766431B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201400003A (es) | Una nueva composición terapéutica que contiene apomorfina como ingrediente activo | |
| DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| BR112015009228A8 (pt) | Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção | |
| ECSP12012171A (es) | Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| BR112012023021A2 (pt) | compostos de indazol e seus usos | |
| ECSP14013155A (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
| BR112015019307A2 (pt) | derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada | |
| NI201200196A (es) | Agentes terapéuticos 976 | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| AR128434A2 (es) | Composiciones y métodos de absorción transmucosa | |
| CR20160116A (es) | Método para tratar onicomicosis con hidroxipropil quitasano | |
| CL2015000310A1 (es) | Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg. | |
| BR112015004127A2 (pt) | sais de composto benzotiazolona como agonista de beta-2-adrenorreceptor | |
| TN2013000503A1 (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| MY166773A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia |